Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesActinogen Medical Ltd

Actinogen Medical Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.041 AUD -0.00 ( 4.65%)
Last update at 2026-11-06T05:10:00Z
VOLUME
8982274
Market Cap
166.59M

Momentum Score

…

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.04
Low
0.04
High
52 Week Price Range
0.03
Low
0.07
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Actinogen Medical Ltd is an Australian clinical-stage biopharmaceutical company developing therapies for cognitive impairment and neurodegenerative disorders, principally Xanamem, an oral inhibitor of 11β-HSD1 designed to reduce brain cortisol. Long-term growth may benefit from successful progression through pivotal trials, regulatory approval and potential licensing or collaborations, which could support commercialisation and make the company attractive to investors seeking exposure to novel approaches in Alzheimer’s disease and cognitive decline.

Key risks include clinical and regulatory failure, lack of marketed products, ongoing funding and dilution risk, and strong competition in the neurodegenerative therapeutics sector.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.04
Dividend Yield
-
Revenue TTM
12.67M
Revenue Per Share
0.00
Gross Profit TTM
12.67M
Debt / Equity
0.22
ROE
-77.46%
Net Debt
-11.95M
ROCE
-130.99%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -28.05M -14.73M -22.98M -10.75M -9.50M
Net income -15.38M -14.73M -13.04M -10.75M -9.52M
Selling general administrative 8.67M 2.03M 1.73M 6.57M 4.56M
Selling and marketing expenses - 6.10M 5.50M - -
Gross profit -0.42M 5.49M 9.93M - -
Reconciled depreciation 0.42M 0.42M 0.42M 0.41M 0.40M
Ebit -28.11M -15.35M -13.26M -10.74M -9.48M
Ebitda -27.69M -15.01M -12.84M -10.33M -9.08M
Depreciation and amortization 0.42M 0.34M 0.42M 0.41M 0.40M
Operating income -28.11M -14.93M -12.84M -10.74M -9.48M
Other operating expenses 28.11M 20.42M 22.77M 15.87M 13.17M
Interest expense 0.47M 0.05M 0.02M 0.02M 0.02M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.50M 0.69M 0.29M 0.37M 0.04M
Net interest income 0.03M 0.64M 0.27M 0.35M 0.02M
Income tax expense -12.67M -5.49M -9.93M 4.79M 0.02M
Total revenue - 5.49M 9.93M 0.37M 0.04M
Total operating expenses 27.69M 20.42M 22.77M 15.87M 13.17M
Cost of revenue 0.42M - 0.42M - -
Total other income expense net 0.06M 0.20M -10.14M 4.77M -0.02M
Net income from continuing ops -15.38M -14.73M -13.04M -10.75M -9.50M
Net income applicable to common shares - -14.73M -13.04M -10.75M -9.50M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 29.56M 24.48M 21.31M 15.21M 23.31M
Intangible assets 1.47M 1.78M - 2.41M 2.72M
Other current assets 0.10M - 0.11M - -
Total liab 8.18M 6.15M 1.62M 1.80M 1.57M
Total stockholder equity 21.37M 18.34M 19.70M 13.41M 21.74M
Other current liab 2.20M - 0.70M 0.70M 0.58M
Common stock 137.91M - 100.02M 78.71M 76.94M
Capital stock 137.91M 101.25M - 78.71M 76.94M
Retained earnings -111.85M -96.47M -81.74M -68.69M -57.94M
Other assets - - 0.00M - -
Cash 16.73M 16.50M 9.45M 8.46M 16.37M
Cash and equivalents - - - 7.18M 12.10M
Total current liabilities 8.10M 5.96M 1.36M 1.80M 1.48M
Current deferred revenue - - - -0.09M -0.08M
Net debt -11.95M - -9.13M -8.37M -16.21M
Short term debt 4.70M - 0.06M 0.09M 0.08M
Short long term debt 4.61M 3.01M - - -
Short long term debt total 4.78M - 0.32M 0.09M 0.17M
Other stockholder equity -19.97M - -10.48M -14.96M -23.94M
Property plant equipment - - - 0.11M 0.17M
Total current assets 27.92M 22.43M 18.88M 12.69M 20.42M
Net tangible assets - - - 11.00M 19.02M
Net receivables 11.08M - 9.32M 4.23M 4.05M
Accounts payable 1.20M 1.93M 0.60M 1.10M 0.90M
Accumulated other comprehensive income 15.28M - 11.89M 3.39M 2.74M
Non currrent assets other - - 2.09M -2.52M -2.89M
Non current assets total 1.64M 2.05M 2.44M 2.52M 2.89M
Capital lease obligations 0.17M 0.26M - 0.09M 0.17M
Long term debt total - - - 0.00M 0.09M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.04M -0.01M -0.04M -0.00M
Change to liabilities - - - 0.25M 0.69M
Total cashflows from investing activities -0.01M -0.04M -0.01M -0.04M -0.00M
Net borrowings 1.10M 3.00M - -0.08M -0.07M
Total cash from financing activities 17.80M 14.65M 17.95M 0.82M 12.42M
Change to operating activities - - - 0.06M 0.03M
Net income -15.38M -14.73M -13.04M -10.75M -9.50M
Change in cash 0.23M 7.05M 0.99M -7.91M 2.95M
Begin period cash flow 16.50M 9.45M 8.46M 16.37M 13.42M
End period cash flow 16.73M 16.50M 9.45M 8.46M 16.37M
Total cash from operating activities -17.56M -7.56M -16.95M -8.70M -9.52M
Issuance of capital stock 17.55M 12.24M 19.11M 0.90M 13.32M
Depreciation 0.42M - 0.42M 0.41M 0.40M
Change to account receivables -5.26M 3.50M -5.20M -0.18M -2.41M
Sale purchase of stock -0.85M -0.53M -1.06M -0.83M -0.83M
Other cashflows from financing activities -0.07M -0.06M -0.09M 0.75M -0.07M
Change to netincome - - - 1.52M 1.27M
Capital expenditures 0.01M 0.04M 0.01M 0.04M 0.00M
Change in working capital -4.74M 5.08M -5.62M -0.18M -2.41M
Stock based compensation - - 1.31M 1.52M 1.29M
Other non cash items 2.14M -12.64M 1.29M 1.65M -0.42M
Free cash flow -17.57M -7.59M -16.96M -8.73M -9.52M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ACW
Actinogen Medical Ltd		 -0.00
4.65%		 0.04 - 25.97 13.14 7.25 218.33 -9.95
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Actinogen Medical Ltd

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

109 Pitt Street, Sydney, NSW, Australia, 2000

61 2 8964 7401

https://actinogen.com.au

Name Title Year Born
Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D. MD, CEO & Director 1960
Mr. Jeff Carter BFinAdmin, MAppFin Chief Financial Officer 1958
Ms. Tamara Miller Sr. VP of Product Devel. NA
Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. Chief Medical Officer NA
Mr. Michael Roberts Head of Investor Relations & Corp. Communications NA
Ms. Therese Russell Head of People & Infrastructure NA
Dr. Christian Toouli Head of Bus. Devel. NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD Company Sec. 1963
Dr. Dana C. Hilt M.D. Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board 1953
Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. Head of Clinical Pharmacology & Lead Physician and Depression NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…